Sema4 Holdings Corp. (SMFR): Price and Financial Metrics
GET POWR RATINGS... FREE!
SMFR Stock Price Chart Interactive Chart >
SMFR Price/Volume Stats
Current price | $2.16 | 52-week high | $15.21 |
Prev. close | $1.98 | 52-week low | $1.49 |
Day low | $1.94 | Volume | 1,618,600 |
Day high | $2.17 | Avg. volume | 1,734,275 |
50-day MA | $2.41 | Dividend yield | N/A |
200-day MA | $5.20 | Market Cap | 528.61M |
Sema4 Holdings Corp. (SMFR) Company Bio
Sema4 Holdings Corp., doing business as Sema4, develops and operates health intelligence software solution that helps in diagnosis, treatment, and prevention of disease. The company offers solutions, such as Sema4, a solution that helps in treatment of the diseases; Centrellis, an analytics platform that generate complete understanding of disease and wellness and extract individualized insights into human health, starting with reproductive health and oncology; Sema4 Signal, a solution that provides data driven care solutions with analytics, digital tools, and exome based somatic and hereditary cancer genomic test; Biopharma, a solution that offers portfolio of health information, pre-clinical and clinical trial support, analytics for actionable insights, and advance sequencing services. It offers noninvasive prenatal select, a blood test for determining baby's health; expanded carrier screen, a carrier screen for more than 280 inherited conditions if one is pregnant or planning for pregnancy; and CarrierCheck, a genetic screen for 67 inherited conditions to know how DNA could affect the children. The company also provides Natalis newborn screen, a home-test to know baby's health by screening for 193 childhood diseases; Solid Tumor panel to analyze cancer driven genes; and test catalogue, a comprehensive offering of genetic and genomic tests. In addition, it owns and operates Centrellis, an analytics platform that generate complete understanding of disease and wellness and extract individualized insights into human health, starting with reproductive health and oncology. The company's solutions include women's health, oncology, expanded carrier screen, noninvasive prenatal select, Natali's newborn screen, hereditary cancer. Sema4 Holdings Corp. is based in Stamford, Connecticut.
Latest SMFR News From Around the Web
Below are the latest news stories about Sema4 Holdings Corp that investors may wish to consider to help them evaluate SMFR as an investment opportunity.
Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the fourth quarter and full year 2021 after the market close on Monday, March 14, 2022. On the same day, Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4, and Isaac Ro, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET |
Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision MedicineInnovators in the application of multi-omics to drug discovery – including phenomics and genomics – to initiate up to 10 therapeutic programs Sema4 Founder & CEO Eric Schadt and BioSymetrics Co-Founder and CEO Anthony Iacovone discuss the collaboration between the two companies STAMFORD, Conn. and BOSTON and TORONTO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and BioSymetrics, a phenomics-driven drug discovery com |
Sema4 to Participate at Two Upcoming Investor Conferences in FebruarySTAMFORD, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following virtual investor conferences: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFireside chat and 1x1s on Thursday, February 17th, 2022 at 10:00 a.m. ET SVB Leerink 11th Annual Global Healthcare ConferenceFormal presentation and 1x1s on Friday, February 18th, 2 |
Sema4 Announces Plans to Strengthen its Market Access Team to Drive Improved Commercial and Reimbursement Capabilities30-year industry veteran, Jerry Conway, joins Sema4 as Senior Vice President of Market Access to lead the team Jerry Conway Jerry Conway joins Sema4 as Senior Vice President of Market Access STAMFORD, Conn., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced plans to strengthen its Market Access team to drive increased market access for the company’s platform. The team’s key initiatives include improving c |
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data PlatformBusiness combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify transaction and Sema4 balance sheet Katherine Stueland, CEO of GeneDx and former CCO of Invitae, to join Sema4 as Co-CEO, alongside Eric Schadt, PhD, and become a member of Sema4’s Board of Directors Director Jason Ryan, former CFO of Foundation Medicine, to assume role of Executive Chair of Sema4’s Board o |
SMFR Price Returns
1-mo | -4.42% |
3-mo | -37.21% |
6-mo | -67.22% |
1-year | -82.94% |
3-year | N/A |
5-year | N/A |
YTD | -51.57% |
2021 | -59.60% |
2020 | N/A |
2019 | N/A |
2018 | N/A |
2017 | N/A |
Loading social stream, please wait...